GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Cyclically Adjusted PS Ratio

Vicore Pharma Holding AB (OSTO:VICO BTA) Cyclically Adjusted PS Ratio : (As of Jul. 14, 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 30.05

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 30.05 25.27

Competitive Comparison of Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio falls into.


;
;

Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.078/132.8245*132.8245
=0.078

Current CPI (Mar. 2025) = 132.8245.

Vicore Pharma Holding AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.000 99.995 0.000
201509 0.026 100.228 0.034
201512 0.018 100.276 0.024
201603 0.015 100.751 0.020
201606 0.019 101.019 0.025
201609 0.018 101.138 0.024
201612 0.023 102.022 0.030
201703 0.022 102.022 0.029
201706 0.022 102.752 0.028
201709 0.020 103.279 0.026
201712 0.018 103.793 0.023
201803 0.000 103.962 0.000
201806 0.013 104.875 0.016
201809 0.011 105.679 0.014
201812 0.003 105.912 0.004
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 9.169 132.205 9.212
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.449 132.987 0.448
202503 0.078 132.825 0.078

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB  (OSTO:VICO BTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines